Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
Stopped early · Phase 1
Conditions studied: Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
In brief
The goal of this clinical trial is to learn about the safety and preliminary antitumor activity of zanzalintinib in combination with AB521 (doublet) and in combination with AB521 plus nivolumab (triplet) in participants with advanced ccRCC or other advanced solid tumors. The main questions it aims to answer are: * The recommended doses (RDs) * The safety and tolerability * The PK and the preliminary efficacy
Key facts
- Study ID
- NCT06191796
- Run by
- Exelixis
- People needed
- 25
- Starts
- 2024-01-25
- Expected to finish
- 2025-05-12
- Last updated by the study team
- 2025-06-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Exelixis Site #8 — Los Angeles, California, United States
- Exelixis Site #9 — Miami, Florida, United States
- Exelixis Clinical Site #1 — Orlando, Florida, United States
- Exelixis Site #11 — Tampa, Florida, United States
- Exelixis Site #6 — Scarborough, Maine, United States
- Exelixis Site #5 — St Louis, Missouri, United States
- Exelixis Clinical Site #3 — New Hyde Park, New York, United States
- Exelixis Site #14 — New York, New York, United States
- Exelixis Site #13 — Shirley, New York, United States
- Exelixis Site #15 — The Bronx, New York, United States
- Exelixis Clinical Site #2 — Nashville, Tennessee, United States
- Exelixis Clinical Site #16 — Salt Lake City, Utah, United States
- Exelixis Site #4 — Spokane, Washington, United States
- Exelixis Site #12 — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.